Drugs / Human interferon α1b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06363370 | Mar 2024 → Jun 2027 expected | respiratory syncytial virus infectious disease | Kexing Biopharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human interferon α1b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06363370 ↗ |
| Known as | GB05 | “To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.” NCT06363370 ↗ |